





Severe burns are one of the most complex conditions to address in clinical and rehabilitation settings. Beyond the initial tissue damage, the recovery process can be long and challenging, characterised by pain, itching, scarring, and functional limitations that significantly impact patients' quality of life.
In recent years, photobiomodulation has attracted growing interest as a potential adjunct to conventional treatments due to its ability to modulate certain biological processes involved in tissue repair. This is the context of a recent study published in the journal Life, which evaluated the use of MLS® Laser Therapy in patients with severe burns, providing new evidence on the potential contribution of this technology to the healing and rehabilitation process.
According to the World Health Organisation, every year over 11 million people worldwide require medical treatment for burns, while approximately 180,000 deaths are related to these injuries.
When burns affect large areas or deep tissue, the clinical challenge is not simply achieving wound closure.
Recovery involves multiple aspects:
For this reason, treating severe burns requires the involvement of multiple professionals and an integrated approach that includes local care, pharmacological management, surgery when necessary, and early rehabilitation.
Photobiomodulation uses specific wavelengths of light to stimulate biological processes involved in tissue repair.
Available evidence suggests that light absorption at cellular level can promote ATP production, modulate the inflammatory response, and support tissue regeneration processes.
The most studied biological effects include the following:
MLS® technology synchronises two laser emissions:
According to the study authors, this combination allows associating anti-inflammatory, anti-oedema, and analgesic effects within a single therapeutic application.
The study was conducted at the “Bagdasar-Arseni” Teaching Emergency Hospital in Bucharest and involved 65 adult patients with grade IIA-IIB and III burns.
Participants were divided into two groups:
The primary objective was to evaluate the time required to achieve complete wound re-epithelialisation.
Secondary endpoints also analysed wound surface reduction, pain, itching, scar quality, functional independence, and quality of life.
In the group treated with MLS® Laser Therapy, the protocol included:
The use of a robotic scanner allowed uniform energy distribution even over large and irregular areas, a particularly valuable feature in burn management.

The most significant result concerns the time required to achieve complete re-epithelialisation.
According to the authors, MLS® Laser Therapy remained associated with significantly better results even after statistical adjustment for clinical factors such as burn extension, wound depth, and the presence of diabetes.
One of the most interesting aspects of the study is that the observed benefits did not only concern the speed of healing.
Patients treated with MLS® Laser Therapy also showed significant improvements in several clinical and functional parameters, including:
This finding appears particularly relevant in the rehabilitation setting, where the goal is not only to promote wound healing, but also to enable the patient to recover functionality, autonomy, and participation in daily activities more quickly.
Although further prospective studies are needed to confirm and further explore these results, the research published in Life represents one of the first comparative studies dedicated to the use of MLS® Laser Therapy in patients with severe burns.
The data suggest a potential contribution of photobiomodulation not only to wound healing but also to symptom management and functional recovery, key aspects of the modern multidisciplinary approach to burn rehabilitation.
In this context, MLS® Laser Therapy emerges as a technology deserving of attention and further scientific investigation, especially in contexts where the clinical objective is not merely wound closure but overall patient recovery..

Advancements with Photobiomodulation in Post-Burn Management/Rehabilitation: A Comparative Study on Multiwave Locked System (MLS) LASER Therapy Outcomes
R.-L. Postoiu, C. Popescu, S. Marinescu, G. Onose
Life, 16(4), 611, 2026






L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.